MannKind Overview
- Year Founded
-
1991
- Status
-
Public
- Employees
-
592
- Stock Symbol
-
MNKD
- Investments
-
5
- Share Price
-
$4.07
- (As of Wednesday Closing)
MannKind General Information
Description
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Contact Information
Website
www.mannkindcorp.comCorporate Office
- 1 Casper Street
- Danbury, CT 06810
- United States
Corporate Office
- 1 Casper Street
- Danbury, CT 06810
- United States
MannKind Timeline
MannKind Stock Performance
As of 18-Nov-2026, MannKind’s stock price is $4.07. Its current market cap is $1.31B with 322M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.07 | $4.07 | $2.23 - $6.51 | $1.31B | 322M | 3.93M | -$0.24 |
MannKind Financials Summary
As of 30-Sep-2026, MannKind has a trailing 12-month revenue of $413M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,473,741 | 1,600,963 | 1,933,941 | 1,117,762 |
| Revenue | 413,371 | 348,966 | 285,504 | 198,962 |
| EBITDA | (7,639) | 43,460 | 63,046 | 12,957 |
| Net Income | (74,822) | 5,863 | 27,588 | (11,938) |
| Total Assets | 722,616 | 792,182 | 393,843 | 475,198 |
| Total Debt | 330,728 | 367,440 | 50,119 | 272,624 |
MannKind Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MannKind Comparisons
Industry
Financing
Details
MannKind Competitors (50)
One of MannKind’s 50 competitors is Regenerative Medical Solutions, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenerative Medical Solutions | Venture Capital-Backed | Madison, WI | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands |
MannKind Patents
MannKind Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236643-A1 | Methods for treating non-tuberculous mycobacterial infection | Pending | 08-May-2025 | ||
| WO-2026164905-A1 | Stabilization apparatus for a dry powder vessel | Pending | 28-Jan-2025 | ||
| US-20260207630-A1 | Furosemide formulations | Pending | 13-Jan-2025 | ||
| WO-2026142985-A1 | Methods for the manufacture of diketopiperazine derivatives | Pending | 23-Dec-2024 | ||
| WO-2026064480-A1 | Method and composition for treating lung diseases | Pending | 18-Sep-2024 | A61K9/0075 |
MannKind Signals
MannKind Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
MannKind Investments & Acquisitions (5)
MannKind’s most recent deal was a Merger/Acquisition with ScPharmaceuticals for . The deal was made on 07-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ScPharmaceuticals | 07-Oct-2025 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| V-Go Insulin Delivery Device | 17-May-2022 | Merger/Acquisition | Therapeutic Devices | ||
| QrumPharma | 07-Dec-2020 | Merger/Acquisition | Drug Discovery | ||
| Pfizer (Insulin Assets) | 22-Jun-2009 | Corporate Asset Purchase | Buildings and Property | ||
| Allecure | 12-Dec-2001 | Merger/Acquisition | Pharmaceuticals |
MannKind ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
29.76 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
MannKind Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| ScPharmaceuticals | Burlington, MA | 2013 |
MannKind FAQs
-
When was MannKind founded?
MannKind was founded in 1991.
-
Where is MannKind headquartered?
MannKind is headquartered in Danbury, CT.
-
What is the size of MannKind?
MannKind has 592 total employees.
-
What industry is MannKind in?
MannKind’s primary industry is Drug Discovery.
-
Is MannKind a private or public company?
MannKind is a Public company.
-
What is MannKind’s stock symbol?
The ticker symbol for MannKind is MNKD.
-
What is the current stock price of MannKind?
As of 18-Nov-2026 the stock price of MannKind is $4.07.
-
What is the current market cap of MannKind?
The current market capitalization of MannKind is $1.31B.
-
What is MannKind’s current revenue?
The trailing twelve month revenue for MannKind is $413M.
-
Who are MannKind’s competitors?
Regenerative Medical Solutions, AnTolRx, Apexian Pharmaceuticals, Altimmune, and uniQure are some of the 50 competitors of MannKind.
-
What is MannKind’s annual earnings per share (EPS)?
MannKind’s EPS for 12 months was -$0.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process